# Phase I/II Study of KP-100IT in Acute Spinal Cord Injury

> **NCT02193334** · PHASE1,PHASE2 · COMPLETED · sponsor: **Kringle Pharma, Inc.** · enrollment: 45 (actual)

## Conditions studied

- Spinal Cord Injuries

## Interventions

- **DRUG:** KP-100IT
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02193334
- **Lead sponsor:** Kringle Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-30
- **Primary completion:** 2017-12-21
- **Final completion:** 2018-07-31
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2019-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02193334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02193334, "Phase I/II Study of KP-100IT in Acute Spinal Cord Injury". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02193334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*